Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: A randomized controlled study

Supportive Care in Cancer

Volumn 20, Issue 8, 2012, Pages 1745-1753

  Kamath, Jayesh ^a   Feinn, Richard ^a   Winokur, Andrew ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer related fatigue; Quality of life; Thyrotropin releasing hormone; TRH

Indexed keywords

PLACEBO; PROTIRELIN;

6 MINUTE WALKING TEST; ADULT; ARTICLE; CANCER FATIGUE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOT FLUSH; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; LEED SLEEP QUESTIONNAIRE; LOW DRUG DOSE; MALE; MIGRAINE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROFILE OF MOOD STATES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; URINARY URGENCY; VISUAL ANALOG SCALE;

CROSS-OVER STUDIES; FATIGUE; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; THYROTROPIN-RELEASING HORMONE; TREATMENT OUTCOME;

EID: 84863981956     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1268-8     Document Type: Article

References (39)

1. National Institute of Health State-of-the-Science Conference Statement (July 15-17, 2002). Available from http://consensus.nih.gov/2002/ 2002CancerPainDepressionFatigueSOS022PDF.pdf
2. Hofman M, Ryan JL, Figueroa-Moseley CD et al (2007) Cancerrelated fatigue: the scale of the problem. Oncologist 12(suppl 1):4-10
3. Mock V, Atkinson A, Barsevick A et al (2000) NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14(11A):151-161
4. Wagner LI, Cella D (2004) Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 91(5):822-828
5. Bower JE, Ganz PA, Desmond KA et al (2006) Fatigue in longterm breast cancer survivors: a longitudinal investigation. Cancer 106(4):751-758
6. Morrow GR, Hickok JT, Roscoe J et al (2003) Differential effects of paroxetine on fatigue and depression: a randomized, doubleblind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 21 (24):4635-4641
7. Minton O, Richardson A, Sharpe M et al (2010) Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 7:CD006704
8. Barsevick A, Frost M, Zwinderman A et al (2010) I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 19(10):1419-1427
9. Bower JE (2007) Cancer-related fatigue: links with inflammation in cancer patients andsurvivors. Brain Behav Immun 21(7):863-871
10. Gary KA, Sevarino KA, Yarbrough GG et al (2003) The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther 305:410-416
11. Yarbrough GG, Kamath J, Winokur A et al (2007) Thyrotropinreleasing hormone (TRH) in the neuroaxis: therapeutic effects reflect physiological functions and molecular actions. Med Hypotheses 69:1249-1256
12. Kamath J, Yarbrough GG, Prange AJ et al (2009) The thyrotropinreleasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacol Ther 121(1):20-28
13. Lesage P, Portenoy RK (2002) Management of fatigue in the cancer patient. Oncology (Williston Park) 16(3):373-378
14. WHO (2011) International Classification of Diseases, 10th Revision, Clinical Modification. Centers for Disease Control and Prevention, Atlanta
15. Yellen SB, Cella DF, Webster K et al (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13(2):63-74
16. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology [Supportive care guidelines]. Cancer related fatigue (version I.2011) http://www.nccn.org/professionals/physician-gls/pdf/fatigue.pdf
17. Kamath J, Yarbrough GG, Prange AJ Jr et al (2009) Thyrotropinreleasing hormone can relieve cancer-related fatigue: hypothesis and preliminary observations. J Int Med Res 37(4):1152-1157
18. Van Belle S, Paridaens R, Evers G et al (2005) Comparison of proposed diagnostic criteria with FACT-F and VAS for cancerrelated fatigue: proposal for use as a screening tool. Support Care Cancer 13(4):246-254
19. Szuba MP, Amsterdam JD, Fernando AT 3rd et al (2005) Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol 25(4):325-330
20. McNair DM, Lorr M, Droppleman LF (1981) Profile of mood states: manual. Educational and Industrial Testing Service, San Diego
21. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370
22. Enright PL (2003) The six-minute walk test. Respir Care 48 (8):783-785
23. Parrott AC, Hindmarch I (1980) The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigation-a review. Psychopharmacology 71:173-179
24. Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79
25. Snyder PJ, Utiger RD (1972) Response to thyrotropin releasing hormone (TRH) in normal man. J Clin Endocrinol Metab 34 (2):380-385
26. Jacobs LS, Snyder PJ, Wilber JF et al (1971) Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab 33(6):996-998
27. Mellow AM, Sunderland T, Cohen RM et al (1981) Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Psychopharmacology 98:403-407
28. Molchan SE, Mellow AM, Lawlor BA et al (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 100(1):84-89
29. Cramp F, Daniel J (2008) Exercise for the management of cancerrelated fatigue in adults. Cochrane Database Syst Rev 2: CD006145
30. Goedendorp MM, Gielissen MF, Verhagen CA et al (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 1:CD006953
31. Bassiri RM, Utiger RD (1973) Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans. J Clin Invest 52(7):1616-1619
32. Hara J, Gerashchenko D, Wisor JP et al (2009) Thyrotropinreleasing hormone increases behavioral arousal through modulation of hypocretin/orexin neurons. J Neurosci 29(12):3705-3714
33. Parmentier R, Kolbaev S, Klyuch BP et al (2009) Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J Neurosci 29(14):4471-4483
34. Broberger C, McCormick DA (2005) Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci 25 (7):1664-1673
35. Gary KA, Sollars PJ, Lexow N et al (1996) Thyrotropin-releasing hormone phase shifts circadian rhythms in hamsters. Neuroreport 7(10):1631-1634
36. Plotnikoff NP, Prange AJ, Breese GR et al (1972) Thyrotropinreleasing hormone: enhancement of DOPA activity by a hypothalamic hormone. Science 178:417-418
37. Plotnikoff NP, Prange AJ, Breese GR, Anderson MS, Wilson IC (1974) The effects of thyrotropin-releasing hormone on DOPA responses in normal hypophysectomized and thyroidectomized animals. In: Prange AJ (ed) The Thyroid Axis, Drugs and Behavior. Raven, New York, pp 103-113
38. Gutiérrez-Mariscal M, de Gortari P, López-Rubalcava C et al (2008) Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety. Psychoneuroendocrinology 33(2):198-213
39. Winokur A, Amsterday JD, Mihailovic V et al (1982) Improvement in ratings of tension after TRH administration in healthy women. Psychoneuroendocrinology 7:239-244